Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 15/20 | 0.60 |
| ▸ | DRD1 | P21728 | 9/20 | 0.60 |
| ▸ | DRD2 | P14416 | 7/20 | 0.60 |
| ▸ | DRD4 | P21917 | 1/20 | 0.55 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29324541 | 0.91 | DRD3 (0.61) | DRD3DRD1DRD2DRD4 | |
| SCHEMBL1039709 | 0.85 | DRD3 (0.63) | DRD3DRD1DRD2DRD4ACHE | |
| SCHEMBL4552575 | 0.85 | DRD3 (0.60) | DRD3DRD1DRD2DRD4 | |
| SCHEMBL9376682 | 0.84 | DRD2 (0.60) | DRD3DRD2ACHE | |
| SCHEMBL1037156 | 0.84 | DRD3 (0.62) | DRD3DRD1DRD2DRD4ACHE | |
| SCHEMBL9375915 | 0.83 | HTR7 (0.61) | DRD3DRD2ACHE | |
| SCHEMBL31134854 | 0.83 | GRM5 (0.64) | DRD3DRD1DRD2DRD4ACHE | |
| SCHEMBL9376168 | 0.83 | HTR7 (0.61) | DRD3DRD2ACHE | |
| SCHEMBL30183548 | 0.83 | DRD3 (0.57) | DRD3DRD1DRD2DRD4ACHE | |
| SCHEMBL5811132 | 0.83 | GRM5 (0.64) | DRD3DRD1DRD2DRD4ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4400504-A1 | THIOPHENE RING COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences (CN) | 2024-07-17 | — | — | EP | disclosed |
| US-7276508-B2 | Indole derivatives useful for the treatment of CNS disorders | H. LUNDBECK A/S (DK) | 2007-10-02 | — | — | US | disclosed |
| EP-1468996-B1 | Indole derivatives for the treatment of CNS disorders | LUNDBECK & CO AS H (DK) | 2007-09-26 | — | — | EP | disclosed |
| US-20050176729-A1 | Indole derivatives useful for the treatment of CNS disorders | H. LUNDBECK A/S (DK) | 2005-08-11 | — | — | US | disclosed |
| EP-1294710-B1 | INDOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | LUNDBECK & CO AS H (DK) | 2005-06-08 | — | — | EP | disclosed |
| US-6890916-B2 | Indole derivatives useful for the treatment of CNS disorders | H. LUNDBECK A/S (DK) | 2005-05-10 | — | — | US | disclosed |
| EP-1468996-A1 | Indole derivatives for the treatment of CNS disorders | H. Lundbeck A/S (DK) | 2004-10-20 | — | — | EP | disclosed |
| EP-1299380-B1 | INDOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | LUNDBECK & CO AS H (DK) | 2004-06-09 | — | — | EP | disclosed |
| US-20030232822-A1 | Indole derivatives useful for the treatment of CNS disorders | H. LUNDBECK A/S (DE) | 2003-12-18 | — | — | US | disclosed |
| US-20030191133-A1 | Indole derivatives useful for the treatment of CNS disorders | H. LUNDBECK A/S (DK) | 2003-10-09 | — | — | US | disclosed |
| EP-1299380-A1 | INDOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | H. LUNDBECK A/S (DK) | 2003-04-09 | — | — | EP | disclosed |
| EP-1294710-A1 | INDOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | H. LUNDBECK A/S (DK) | 2003-03-26 | — | — | EP | disclosed |
| WO-2002000645-A1 | INDOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | H. LUNDBECK A/S (DK) | 2002-01-03 | — | — | WO | disclosed |
| WO-2001096328-A1 | INDOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | H. LUNDBECK A/S (DK) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176729-A1 | Indole derivatives useful for the treatment of CNS disorders | HTR4, TPH1, SLC6A3 | DRD3 31/4885DRD1 49/4885DRD2 14/4885 |
| US-20030191133-A1 | Indole derivatives useful for the treatment of CNS disorders | TPH1, CHRM1, TPH2 | DRD3 63/4885DRD1 88/4885DRD2 47/4885 |
| US-20030232822-A1 | Indole derivatives useful for the treatment of CNS disorders | CHRM1, TPH1, CHRNA6 | DRD3 136/4885DRD1 285/4885DRD2 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.